Register entry

Revance Therapeutics, Inc.

Data as of · How to read this entry

Registered sites
2
Active NDC listings
1
Live patents
0
Countries
1
Base
United States
Authorisation

Registered operations

Analytical testing2Active ingredient (API) manufacture1Finished drug manufacture1
Sites

Registered establishments

2
EstablishmentAddressRegistered forFEI / DUNS
Revance Therapeutics, Inc.Bldg 261 Rm 144 Moffett Blvd, Moffett Field, California (CA) 94035, United States (USA)Analytical testing3019604545118167565
Revance Therapeutics, Inc.7555 Gateway Boulevard, Newark, California (CA) 94560, United States (USA)Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture3007772056118195550
Catalogue

Marketed products

1
BrandGeneric nameForm / routeNDC
DAXXIFYbotulinum toxin type Ainjection, powder, lyophilized, for solution, intramuscular72960-112BLA
Compare

Comparable companies in United States

Enquiry

Common questions

Is Revance Therapeutics, Inc. FDA approved?
Revance Therapeutics, Inc. holds 2 FDA-registered establishments in the United States. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are Revance Therapeutics, Inc.'s drugs manufactured?
The FDA register lists Moffett Field, CA; Newark, CA. Registered operations: analytical testing, active ingredient (API) manufacture, finished drug manufacture.
What drugs does Revance Therapeutics, Inc. make?
1 product is listed under Revance Therapeutics, Inc. in the openFDA NDC Directory, most often as injection, powder, lyophilized, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.